Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

BackTable Tumor Board

S02 Ep. 12 Tumor Board: Multidisciplinary Management of Testicular Germ Cell Tumors with Dr. Nabil Adra and Dr. Richard Matulewicz

27 May 2025

Description

What does it take to deliver truly personalized, multidisciplinary care in testicular cancer? Get an inside look in this episode of BackTable Tumor Board, where renowned testicular cancer experts Dr. Nabil Adra and Dr. Richard Matulewicz join host Dr. Aditya Bagrodia for a virtual tumor board session on the nuanced management of germ cell tumors. --- This podcast is supported by: ⁠Ferring Pharmaceuticals --- SYNPOSIS The expert panel uses specific patient cases to review their decision-making processes on the use of surgery, chemotherapy, and radiation. They highlight the importance of a multidisciplinary approach, particularly for advanced disease and challenging surgical scenarios. The episode reviews patient-specific factors, standard treatment protocols, post-treatment surveillance, and the latest research. This episode also highlights the benefits of personalized cancer care. --- TIMESTAMPS 00:00 - Case Presentation: 23-Year-Old Male with Testicular Mass09:53 - Surveillance vs. Adjuvant Therapy Debate13:53 - Recurrence, Comprehensive Staging, and Next Steps23:09 - Case Study: 44-Year-Old with Mixed Non-Seminoma Germ Cell Tumor27:47 - Surveillance and Surgery Recommendations28:11 - Case Study: 17-Year-Old with Developmental Delay and Cancer30:10 - Chemotherapy, Surgical Timing, and Prognosis44:58 - Case Study: 21-Year-Old with Scrotal Swelling47:12 - Surgical Considerations and Multidisciplinary Approach --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.